Angiogenesis-modulating compositions and uses

• US 20030022819A1
• Filed: 06/18/2001
• Published: 01/30/2003
• Est. Priority Date: 06/16/2000
• Status: Abandoned Application

• Current Assignee: Curis, Inc.
• Original Assignee: Curis, Inc.
• Inventors: Sanicola-Nadel, Michele, Ling, Leona E.
• Application Number:
  US09/883,848
• Publication Number:
  US 20030022819A1
• Time in Patent Office: Days
• US Class Current: 514/7
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4025 not condensed and containing further heterocyclic rings, e.g. cromakalim
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/1833 Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/1891 Angiogenesic factors; Angiogenin
• CPC Class Codes: A61K 38/195 Chemokines, e.g. RANTES
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/43581 from Drosophila
• CPC Class Codes: C07K 14/461 from fish
• CPC Class Codes: C07K 14/465 : from birds
• CPC Class Codes: C07K 14/47 : from mammals
• CPC Class Codes: C07K 16/18 : against material from animals or humans

Abstract

Hedgehog agonists and antagonists can be used to regulate angiogenesis, and have utility in treating tissue repair and cancer, and to prevent angiogenesis driven pathologies.

Claims

1. A method of promoting angiogenesis in a subject animal comprising administering to the subject an angiogenic amount of a hedgehog polypeptide or agonist thereof.

2. The method of claim 1, wherein the step of administering comprises contacting the hedgehog polypeptide or agonist with a mesenchymal cell of the subject.

3. The method of claim 1, comprising administering to the subject a polypeptide including a hedgehog amino acid sequence, which hedgehog sequence directs the binding of the polypeptide to a patched receptor polypeptide and/or induces alkaline phosphatase activity in C3H10T1/2 cells.

4. The method of claim 1, comprising administering to the subject a polypeptide including a hedgehog amino acid sequence having at least 60% amino acid identity with SEQ ID No. 10-18 or 20.

5. The method of claim 1, comprising administering to the subject a polypeptide including a hedgehog amino acid sequence encoded by a coding sequence which hybridizes under stringent conditions to any of SEQ ID No. 1-9 or 19.

6. The method of claim 1, comprising administering to the subject a polypeptide including a hedgehog amino acid sequence represented by SEQ ID No. 26.

7. The method of any of claims 3 -7, wherein the hedgehog sequence includes at least 50 resdiues of an extracellular domain of a hedgehog protein.

8. The method of any of claims 3 -7, wherein the polypeptide is derivatized with one or more chemical moieties.

9. The method of claim 8, wherein the chemical moiety is a polyalkylene glycol polymer.

10. The method of claim 8, wherein the chemical moiety is a hydrophobic moiety.

11. The method of claim 10, wherein the hydrophobic moiety is a lipid.

12. The method of claim 8, wherein the chemical moiety is one or more phosphate groups.

13. The method of claim 8, wherein the chemical moiety is one or more acetyl groups.

14. The method of claim 8, wherein the chemical moiety is one or more sugar or carbohydrate groups.

15. The method of claim 8, wherein the chemical moieties are any combination of phosphate, acetyl, sugar, carbohydrate, or hydrophobic moieties.

16. The method of claim 4, wherein the method further comprises administering an agent that enhances agonistic properties of the hedgehog therapeutic.

17. The method of claim 16, wherein the agent is an angiogenic factor selected from the group consisting of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), angiopoietin 1, angiopoietin 2, monocyte chemotactic protein-1 (MCP-1).

25. The method of claim 1, wherein the hedgehog agonist is a small organic molecule.

26. The method of claim 25, wherein the hedgehog agonist has a molecular weight less than 2500 amu.

27. The method of claim 25, wherein the hedgehog agonist is represented by general formula (XII):

Formula XII

wherein, as valence and stability permit,

Ar and Ar′

independently represent substituted or unsubstituted aryl or heteroaryl rings;

Y, independently for each occurrence, may be absent or represent —

N(R)—

, —

O—

, —

S—

, or —

Se—

;

X can be selected from —

C(═

O)—

, —

C(═

S)—

, —

S(O₂)—

, —

S(O)—

, —

C(═

NCN)—

, —

P(═

O)(OR₂)—

, and a methylene group optionally substituted with 1-2 groups such as lower alky, alkenyl, or alkynyl groups;

M represents, independently for each occurrence, a substituted or unsubstituted methylene group, such as —

CH₂—

, —

CHF—

, —

CHOH—

, —

CH(Me)—

, —

C(═

O)—

, etc., or two M taken together represent substituted or unsubstituted ethene or ethyne;

R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, heteroaralkyl, alkynyl, alkenyl, or alkyl, or two R taken together may form a 4- to 8-membered ring, e.g., with N;

Cy and Cy′

independenly represent substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl, including polycyclic groups;

i represents, independently for each occurrence, an integer from 0 to 5, preferably from 0 to 2; and

n, individually for each occurence, represents an integer from 0 to 10, preferably from 0 to 5.

28. The method of any of claims 3-7, comprising administering a nucleic acid sequence encoding the polypeptide.

18. A method of inhibiting angiogenesis in a subject animal comprising administering to the subject an antiangiogenic amount of a hedgehog antagonist.

19. The method of claim 18, comprising administering a polypeptide including one or more antigen binding domains which bind to and inhibit hedgehog signalling.

20. The method of claim 18, comprising administering a polypeptide including one or more antigen binding domains which bind to patched and inhibit hedgehog signalling.

21. The method of claim 18, comprising administering a polypeptide including one or more antigen binding domains which bind to smoothened and inhibit hedgehog signalling.

22. The method of claim 19, 20 or 21, wherein the antigen binding domain is part of a an antibody structure selected from the group consisting of a humanized antibody homology, a human antibody homolog, a chimeric antibody homolog and fragments thereof.

23. The method of claim 18, comprising administering a finctional antagonist of a hedgehog therapeutic.

24. The method of claim 18, or 20, wherein the subject has a condition selected from the group consisting of a malignant tumor, retinopathy, macular degeneration, a nonmalignant tumor, rheumatoid arthritis, osteoarthritis, neovascular glaucoma, keloids, Crohn'"'"'s disease, ulcerative colitis, and psoriasis.

30. The method of claim 18, wherein the hedgehog antagonist is a small organic molecule.

31. The method of claim 30, wherein the hedgehog antagonist has a molecular weight less than 2500 amu.

32. The method of claim 30, wherein the hedgehog antagonist is represented by one or more of formulas I-XI.

33. The method of claim 30, wherein the hedgehog antagonist is represented by general formula (I):

34. The method of claim 30, wherein the hedgehog antagonist is represented by general formula (VI):

29. The method of claim 29, wherein the nucleic acid sequences encoding the polypeptide are introduced via a viral vector, via lipofection, and/or as naked DNA.